Brincidofovir (BCV) is an oral antiviral being developed for the treatment of smallpox under the U.S. Food and Drug Administration’s Animal Efficacy Rule, which allows for testing of investigational drugs in animal models to support effectiveness in diseases that are not ethical or feasible to study in humans.

How does BCV work in smallpox?

BCV is designed to improve treatment of viral infections by enhancing drug delivery to the intracellular site of viral replication. BCV effectively penetrates cells via its lipid conjugate, releasing the nucleotide analog cidofovir, which then acts to inhibit virus replication.

Results from studies of brincidofovir in rabbit and mouse models of smallpox showed improved survival, even when treatment was initiated late in the course of disease. Learn more about the studies here and here.